company background image
VCEL logo

Vericel NasdaqGM:VCEL Stock Report

Last Price

US$45.83

Market Cap

US$2.2b

7D

9.6%

1Y

30.3%

Updated

29 Oct, 2024

Data

Company Financials +

VCEL Stock Overview

A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America.

VCEL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

US$57.14
FV
19.8% undervalued intrinsic discount
26.15%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Updated narrative

Vericel Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vericel
Historical stock prices
Current Share PriceUS$45.83
52 Week HighUS$54.10
52 Week LowUS$32.28
Beta1.67
11 Month Change6.11%
3 Month Change-9.28%
1 Year Change30.27%
33 Year Change-2.41%
5 Year Change149.89%
Change since IPO-95.91%

Recent News & Updates

Recent updates

What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You

Jul 12
What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You

Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11
Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year

Apr 26
It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year

Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Mar 02
Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%

Feb 02
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%

Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit

May 05
Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit

Vericel Corporation: Stock Has Fallen, But Not Enough To Make This A Buy

Oct 10

Vericel Q2 2022 Earnings Preview

Aug 02

Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)

Apr 19
Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)

Vericel - A Disruptive Business With Years Of Growth Remaining

Apr 12

Vericel: In The Middle Of Difficulty Is An Opportunity

Dec 31

Vericel Corporation's (NASDAQ:VCEL) Intrinsic Value Is Potentially 19% Below Its Share Price

Aug 09
Vericel Corporation's (NASDAQ:VCEL) Intrinsic Value Is Potentially 19% Below Its Share Price

Shareholder Returns

VCELUS BiotechsUS Market
7D9.6%-0.2%-0.09%
1Y30.3%27.0%38.6%

Return vs Industry: VCEL exceeded the US Biotechs industry which returned 28.6% over the past year.

Return vs Market: VCEL underperformed the US Market which returned 39.5% over the past year.

Price Volatility

Is VCEL's price volatile compared to industry and market?
VCEL volatility
VCEL Average Weekly Movement6.0%
Biotechs Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market3.0%

Stable Share Price: VCEL has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: VCEL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1989314Nick Colangelovcel.com

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Vericel Corporation Fundamentals Summary

How do Vericel's earnings and revenue compare to its market cap?
VCEL fundamental statistics
Market capUS$2.24b
Earnings (TTM)US$789.00k
Revenue (TTM)US$214.52m

2,848x

P/E Ratio

10.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VCEL income statement (TTM)
RevenueUS$214.52m
Cost of RevenueUS$63.45m
Gross ProfitUS$151.07m
Other ExpensesUS$150.28m
EarningsUS$789.00k

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)0.016
Gross Margin70.42%
Net Profit Margin0.37%
Debt/Equity Ratio0%

How did VCEL perform over the long term?

See historical performance and comparison